Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

INSM

Insmed Inc

Nov 29 • 04:00PM ET

75.73

Dollar change -0.15
Percentage change -0.20	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN GILD RARE NBIX UTHR SRPT EXEL BMRN

| Held by: VTI IWM VB XBI VXF VBK IWO IBB VTWO VHT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.56	Insider Own	2.50%	Shs Outstand	178.90M	Perf Week	2.60%
Market Cap	13.55B	Forward P/E	-	EPS next Y	-4.34	Insider Trans	-16.37%	Shs Float	174.44M	Perf Month	7.73%
Income	-864.28M	PEG	-	EPS next Q	-1.18	Inst Own	105.21%	Short Float	6.94%	Perf Quarter	-0.97%
Sales	342.96M	P/S	39.50	EPS this Y	-0.69%	Inst Trans	8.16%	Short Ratio	7.84	Perf Half Y	37.57%
Book/sh	2.70	P/B	28.02	EPS next Y	19.33%	ROA	-51.17%	Short Interest	12.10M	Perf Year	201.71%
Cash/sh	8.21	P/C	9.23	EPS next 5Y	-	ROE	-890.75%	52W Range	21.92 - 80.53	Perf YTD	144.37%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-4.82%	ROI	-52.93%	52W High	-5.96%	Beta	1.11
Dividend TTM	-	Quick Ratio	5.99	Sales past 5Y	275.45%	Gross Margin	75.77%	52W Low	245.48%	ATR (14)	2.75
Dividend Ex-Date	-	Current Ratio	6.37	EPS Y/Y TTM	-5.41%	Oper. Margin	-205.25%	RSI (14)	58.73	Volatility	2.74% 4.09%
Employees	912	Debt/Eq	2.41	Sales Y/Y TTM	22.13%	Profit Margin	-252.01%	Recom	1.11	Target Price	89.56
Option/Short	Yes / Yes	LT Debt/Eq	2.38	EPS Q/Q	-14.13%	Payout	-	Rel Volume	0.47	Prev Close	75.88
Sales Surprise	0.07%	EPS Surprise	-5.65%	Sales Q/Q	18.15%	Earnings	Oct 31 BMO	Avg Volume	1.54M	Price	75.73
SMA20	5.53%	SMA50	4.92%	SMA200	36.55%	Trades		Volume	719,651	Change	-0.20%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-23-24	Initiated	Truist	Buy	$48
Feb-15-24	Initiated	Wolfe Research	Outperform	$42
Dec-08-23	Initiated	Wells Fargo	Overweight	$55
Nov-20-23	Resumed	JP Morgan	Overweight	$36
Jul-26-23	Initiated	Guggenheim	Buy	$50
Dec-09-22	Initiated	Mizuho	Buy	$28
Dec-07-22	Initiated	Barclays	Overweight	$37
Nov-18-22	Initiated	BofA Securities	Buy	$39
Apr-27-22	Initiated	Goldman	Buy	$56
Dec-06-21	Initiated	JP Morgan	Overweight	$45
Oct-19-21	Resumed	Morgan Stanley	Overweight	$56 → $52
Oct-19-21	Resumed	Monness Crespi & Hardt	Buy	$52
Oct-08-21	Initiated	Cantor Fitzgerald	Overweight	$60
Apr-26-21	Resumed	Credit Suisse	Outperform	$60
Dec-17-20	Initiated	Berenberg	Buy	$48
Oct-12-20	Resumed	Stifel	Buy	$44
Sep-03-19	Initiated	Goldman	Buy	$30
Apr-09-19	Reiterated	H.C. Wainwright	Buy	$43 → $52
Feb-15-19	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform	$40
Jan-17-19	Upgrade	Goldman	Neutral → Buy

Show Previous Ratings

Nov-07-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Nov-06-24 08:00AM	Insmed To Present at November 2024 Investor Conferences (PR Newswire) +5.14%
Nov-04-24 09:15AM	Insmed (INSM) Reliance on International Sales: What Investors Need to Know (Zacks)
Nov-01-24 09:22AM	Do You Believe in the Growth Potential of Insmed (INSM)? (Insider Monkey)
03:03AM	Insmed Inc (INSM) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
01:58AM	Loading…
01:58AM	Q3 2024 Insmed Inc Earnings Call (Thomson Reuters StreetEvents)
01:12AM	Decoding Insmed Inc (INSM): A Strategic SWOT Insight (GuruFocus.com)
Oct-31-24 10:00AM	Insmed (INSM) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
08:15AM	Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:17AM	Insmed: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Insmed Reports Third-Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Oct-30-24 09:15AM	Insmed (INSM) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
Oct-29-24 05:47PM	How to play biotech stocks: Insmed and Wave Life Sciences (Yahoo Finance Video)
Oct-24-24 04:05PM	Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List (PR Newswire)
Oct-23-24 08:00AM	Insmed Unites Across Communities Around the World During Third Annual Global Day of Good (PR Newswire)
10:01AM	Loading…
Oct-17-24 10:01AM	Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	Insmed to Host Third-Quarter 2024 Financial Results Conference Call on Thursday, October 31, 2024 (PR Newswire)
Oct-09-24 05:28PM	Insmed Inc (INSM) Q2 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com)
Oct-08-24 04:05PM	New Subgroup Analyses from Landmark Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis Demonstrate Consistency with Positive Overall Trial Population Results (PR Newswire)
Oct-06-24 09:23AM	Insmed Inc. (INSM): Hedge Funds Are Bullish On This NASDAQ Stock Right Now (Insider Monkey)
Oct-04-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Sep-29-24 06:38AM	Is Insmed Incorporated (INSM) the Best Performing Long Term Stock in 2024? (Insider Monkey)
Sep-26-24 12:25AM	Is Insmed Inc. (INSM) the Best Performing Stock in 2024? (Insider Monkey)
Sep-21-24 10:14AM	Insmed Inc. (INSM): A Top Mid-Cap Biopharma Stock with Compelling Growth Potential (Insider Monkey)
Sep-11-24 05:45AM	Insmed Incorporated (INSM) Surged Following Positive Data For its Drug (Insider Monkey)
Sep-08-24 01:52AM	Insmed Incorporated (INSM): Hedge Funds Are Recommending This Biotech Stock Now (Insider Monkey)
Sep-06-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Aug-29-24 03:30AM	Insmed (INSM) Rose Due to Positive Trial Results (Insider Monkey)
Aug-24-24 02:29PM	Analyst Thinks Marvell Technology (MRVL) Will Benefit from Nvidia's Blackwell Launch (Insider Monkey)
08:00AM	Meta Stock Leads 5 Names Near Buy Points As Market Bounces (Investor's Business Daily)
07:01PM	Loading…
Aug-14-24 07:01PM	Insider Sale: Chief People Strategy Officer Schaeffer Orlov S Nicole Sells Shares of Insmed Inc ... (GuruFocus.com)
Aug-09-24 11:41AM	Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View (Zacks)
01:07AM	Decoding Insmed Inc (INSM): A Strategic SWOT Insight (GuruFocus.com)
Aug-08-24 09:30AM	Compared to Estimates, Insmed (INSM) Q2 Earnings: A Look at Key Metrics (Zacks)
08:10AM	Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:08AM	Insmed: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Insmed Reports Second-Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
Aug-02-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jul-29-24 08:00AM	Insmed to Host Second-Quarter 2024 Financial Results Conference Call on Thursday, August 8, 2024 (PR Newswire)
Jul-25-24 06:39PM	These Signs Show Which Stocks Are Having A Hidden Rally, Says Mark Minervini (Investor's Business Daily)
10:02AM	Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-16-24 08:28AM	Should You Consider Adding Marvell Technology (MRVL) to Your Portfolio? (Insider Monkey)
07:48AM	What Makes Insmed Incorporated (INSM) a Prospective Investment? (Insider Monkey)
06:43AM	Is CCC Intelligent Solutions Holdings (CCCS) a Worthy Stock to Add? (Insider Monkey)
Jul-05-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire) +12.90%
Jul-03-24 11:53AM	More endpoints met in Insmeds Phase III brensocatib trial (Clinical Trials Arena)
09:03AM	Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference (PR Newswire)
Jul-02-24 11:53AM	Pharma companies shape competitive pipeline for bronchiectasis (Clinical Trials Arena)
Jun-27-24 08:00AM	Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 (PR Newswire)
Jun-14-24 07:50AM	Takeda circles a leukemia drug; J.P. Morgan moves into biotech investing (BioPharma Dive)
Jun-07-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Jun-05-24 08:00AM	Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-30-24 04:05PM	Insmed to Host Commercial Webinar on June 4, 2024 (PR Newswire) +6.41%
08:00AM	Insmed Announces Pricing of $650 Million Public Offering of Common Stock (PR Newswire)
May-29-24 12:20PM	Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data (Zacks) +11.42%
06:05AM	Insmed stocks soar as Phase III lung disease drug exceeds expectations (Clinical Trials Arena)
May-28-24 07:25PM	Insmed CEO on lung disease treatment and path forward (CNBC TV) +118.45%
06:21PM	Insmed Announces Proposed $500 Million Public Offering of Common Stock (PR Newswire)
04:49PM	Insmed Stock More Than Doubled in Value Tuesday Here's Why (Investopedia)
04:02PM	The Next Humira? Insmed Catapults 119% On Its 'Very Attractive' Opportunity In Lung Disease. (Investor's Business Daily)
03:41PM	Insmed stock blasts off over lung condition study results (Yahoo Finance Video)
02:24PM	Chart of the Day: Insmed (CNBC TV)
02:21PM	Insmed Stock Surges on Trial Win for Lung-Condition Drug. We Hit the Mark, CEO Says. (Barrons.com)
01:16PM	Stocks to Watch Tuesday: GameStop, Apple, Nvidia, Hess (The Wall Street Journal)
12:20PM	Insmed, Agios rise; DraftKings, Atlantica fall, Tuesday, 5/28/2024 (Associated Press Finance)
10:58AM	Why Is Inflammatory Diseased-Focused Insmed Stock Soaring On Tuesday? (Benzinga)
10:01AM	Insmed's shares double as lung disease med powers past expectations in phase 3 (FierceBiotech.com)
09:36AM	Insmed Shares Rocket After Drug Eases Lung Disease Symptoms (Bloomberg)
09:04AM	Insmed Catapults 128% After Proving Its Theory In A 'Large, Untapped' Lung Disease Market (Investor's Business Daily)
09:00AM	Insmed Stock More Than Doubles on Trial Win for Lung-Condition Drug (Barrons.com)
08:40AM	Why Is Insmed (INSM) Stock Up 134% Today? (InvestorPlace)
07:27AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
06:30AM	Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis (PR Newswire)
03:25AM	Nvidia, Apple and GameStop rise premarket; Tesla, DraftKings fall (Investing.com)
May-27-24 06:47PM	Is Insmed Incorporated (NASDAQ:INSM) a Buy According to Hedge Funds? (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
04:00PM	Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis (PR Newswire)
May-20-24 05:58PM	Insmed Lung Infections Treatment Study Shows Improvement (MT Newswires)
04:28PM	Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session (PR Newswire)
May-17-24 07:00PM	Insider Sale: Chief Medical Officer Martina Flammer Sells Shares of Insmed Inc (INSM) (GuruFocus.com)
May-15-24 08:36AM	Goldman Sachs Adjusts Price Target on Insmed to $49 From $40, Maintains Buy Rating (MT Newswires)
May-10-24 03:33PM	Insmed Incorporated (NASDAQ:INSM) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:48PM	Insmed Inc (INSM) Reports Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows Amidst Clinical ... (GuruFocus.com)
11:14AM	Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates (Zacks)
10:36AM	Mizuho Securities Raises Price Target on Insmed to $36 From $35, Keeps Buy Rating (MT Newswires)
May-09-24 11:55AM	INSM Stock Earnings: Insmed Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
10:00AM	Insmed (INSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:15AM	Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:45AM	Insmed's Q1 Net Loss Narrows as Revenue Advances (MT Newswires)
07:16AM	Insmed: Q1 Earnings Snapshot (Associated Press Finance)
07:00AM	Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update (PR Newswire)
May-08-24 10:19AM	Should You Buy Insmed (INSM) Ahead of Earnings? (Zacks)
May-07-24 08:00AM	Insmed To Present at the BofA Securities Health Care Conference 2024 (PR Newswire)
May-03-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
May-02-24 10:01AM	Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-25-24 08:00AM	Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024 (PR Newswire)
Apr-10-24 12:40PM	What Makes Insmed (INSM) a Lucrative Investment? (Insider Monkey)
Apr-05-24 08:00AM	Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (PR Newswire)
Mar-27-24 04:05PM	Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference (PR Newswire)

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Smith Michael Alexander	Chief Legal Officer	Sep 13 '24	Option Exercise	22.76	7,000	159,320	95,727	Sep 16 04:47 PM
Smith Michael Alexander	Chief Legal Officer	Sep 13 '24	Sale	74.35	27,871	2,072,223	67,856	Sep 16 04:47 PM
Flammer Martina M.D.	Chief Medical Officer	Sep 13 '24	Option Exercise	34.03	26,969	917,755	133,103	Sep 16 04:46 PM
Flammer Martina M.D.	Chief Medical Officer	Sep 16 '24	Option Exercise	34.03	13,436	457,227	119,570	Sep 16 04:46 PM
Flammer Martina M.D.	Chief Medical Officer	Sep 12 '24	Option Exercise	34.03	635	21,609	106,769	Sep 16 04:46 PM
Flammer Martina M.D.	Chief Medical Officer	Sep 13 '24	Sale	74.90	26,969	2,019,978	106,134	Sep 16 04:46 PM
Flammer Martina M.D.	Chief Medical Officer	Sep 16 '24	Sale	74.92	13,436	1,006,625	106,134	Sep 16 04:46 PM
Flammer Martina M.D.	Chief Medical Officer	Sep 12 '24	Sale	74.92	635	47,574	106,134	Sep 16 04:46 PM
Smith Michael Alexander	Officer	Sep 13 '24	Proposed Sale	74.60	27,871	2,079,176		Sep 13 04:28 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Sep 10 '24	Option Exercise	10.85	37,575	407,689	137,675	Sep 10 07:49 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Sep 10 '24	Sale	71.50	37,575	2,686,615	100,100	Sep 10 07:49 PM
Schaeffer Orlov S Nicole	Officer	Sep 10 '24	Proposed Sale	71.30	37,575	2,679,097		Sep 10 04:14 PM
Flammer Martina M.D.	Chief Medical Officer	Sep 06 '24	Option Exercise	22.77	149,002	3,393,515	255,136	Sep 10 04:06 PM
Flammer Martina M.D.	Chief Medical Officer	Sep 06 '24	Sale	71.23	149,002	10,613,387	106,134	Sep 10 04:06 PM
Flammer Martina M.D.	Officer	Sep 06 '24	Proposed Sale	71.18	243,920	17,362,225		Sep 06 04:19 PM
McCarthy Daniel Joseph	Officer	Aug 22 '24	Proposed Sale	32.63	34,162	1,114,706		Aug 22 03:57 PM
Smith Michael Alexander	Chief Legal Officer	Aug 12 '24	Option Exercise	15.59	88,070	1,372,844	176,797	Aug 14 04:28 PM
Smith Michael Alexander	Chief Legal Officer	Aug 12 '24	Sale	72.96	88,070	6,425,466	88,727	Aug 14 04:28 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Aug 12 '24	Sale	72.49	9,469	686,408	100,100	Aug 14 04:26 PM
Schaeffer Orlov S Nicole	Officer	Aug 12 '24	Proposed Sale	72.46	9,469	686,119		Aug 12 04:05 PM
Smith Michael Alexander	Officer	Aug 12 '24	Proposed Sale	72.92	88,070	6,422,449		Aug 12 04:01 PM
Flammer Martina M.D.	Chief Medical Officer	Jun 10 '24	Option Exercise	23.75	21,195	503,381	127,329	Jun 12 04:21 PM
Flammer Martina M.D.	Chief Medical Officer	Jun 10 '24	Sale	60.00	21,195	1,271,700	106,134	Jun 12 04:21 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jun 03 '24	Option Exercise	21.09	55,000	1,159,812	163,760	Jun 05 04:23 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jun 03 '24	Sale	55.33	55,000	3,043,150	108,760	Jun 05 04:23 PM
Wise John Drayton	Chief Commercial Officer	May 28 '24	Option Exercise	12.58	6,250	78,625	127,907	May 30 05:46 PM
Wise John Drayton	Chief Commercial Officer	May 28 '24	Sale	49.79	7,852	390,918	121,657	May 30 05:46 PM
Smith Michael Alexander	Chief Legal Officer	May 28 '24	Option Exercise	14.27	38,971	556,079	133,550	May 30 05:45 PM
Smith Michael Alexander	Chief Legal Officer	May 28 '24	Sale	49.53	44,722	2,215,081	88,828	May 30 05:45 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	May 28 '24	Option Exercise	12.58	27,500	345,950	136,260	May 30 05:44 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	May 28 '24	Sale	49.53	27,500	1,362,075	108,760	May 30 05:44 PM
Flammer Martina M.D.	Chief Medical Officer	May 28 '24	Option Exercise	23.66	103,806	2,456,050	209,940	May 30 05:43 PM
Flammer Martina M.D.	Chief Medical Officer	May 30 '24	Option Exercise	23.75	21,195	503,381	127,329	May 30 05:43 PM
Flammer Martina M.D.	Chief Medical Officer	May 28 '24	Sale	49.62	103,806	5,150,854	106,134	May 30 05:43 PM
Flammer Martina M.D.	Chief Medical Officer	May 30 '24	Sale	55.00	21,195	1,165,725	106,134	May 30 05:43 PM
Bonstein Sara	Chief Financial Officer	May 29 '24	Option Exercise	26.57	220,564	5,861,212	358,769	May 30 05:41 PM
Bonstein Sara	Chief Financial Officer	May 28 '24	Option Exercise	26.26	20,724	544,247	326,613	May 30 05:41 PM
Bonstein Sara	Chief Financial Officer	May 29 '24	Sale	50.00	220,564	11,028,200	117,481	May 30 05:41 PM
Bonstein Sara	Chief Financial Officer	May 28 '24	Sale	50.01	20,724	1,036,407	338,045	May 30 05:41 PM
Flammer Martina M.D.	Chief Medical Officer	May 17 '24	Sale	25.09	4,642	116,468	106,134	May 17 04:16 PM
Adsett Roger	Chief Operating Officer	May 17 '24	Sale	25.09	5,945	149,160	149,275	May 17 04:15 PM
Wise John Drayton	Chief Commercial Officer	May 14 '24	Sale	25.47	5,088	129,591	123,259	May 15 04:39 PM
Smith Michael Alexander	Chief Legal Officer	May 14 '24	Sale	25.40	5,093	129,362	94,579	May 15 04:37 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	May 14 '24	Sale	25.53	6,508	166,149	108,760	May 15 04:36 PM
Lewis William	Chair and CEO	May 14 '24	Sale	25.52	22,198	566,493	384,125	May 15 04:34 PM
Flammer Martina M.D.	Chief Medical Officer	May 14 '24	Sale	25.47	10,640	271,001	110,776	May 15 04:33 PM
Bonstein Sara	Chief Financial Officer	May 14 '24	Sale	25.32	11,088	280,748	117,481	May 15 04:32 PM
Adsett Roger	Chief Operating Officer	May 14 '24	Sale	25.50	7,857	200,354	155,220	May 15 04:31 PM
Lewis William	Chair and CEO	Feb 28 '24	Option Exercise	12.58	50,000	629,000	50,500	Feb 29 04:08 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 12 '24	Sale	28.63	4,667	133,616	106,898	Jan 12 04:06 PM
Adsett Roger	Chief Operating Officer	Jan 12 '24	Sale	28.63	5,251	150,336	148,559	Jan 12 04:05 PM
Wise John Drayton	Chief Commercial Officer	Jan 09 '24	Sale	28.78	1,861	53,560	113,829	Jan 11 04:13 PM
Smith Michael Alexander	General Counsel, Senior VP	Jan 09 '24	Sale	28.76	2,373	68,247	86,364	Jan 11 04:11 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jan 09 '24	Option Exercise	20.49	503	10,306	105,652	Jan 11 04:10 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jan 09 '24	Sale	28.85	3,668	105,831	101,984	Jan 11 04:10 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 09 '24	Sale	29.01	4,715	136,782	112,810	Jan 11 04:08 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 10 '24	Sale	28.90	1,245	35,980	111,565	Jan 11 04:08 PM
Bonstein Sara	Chief Financial Officer	Jan 09 '24	Sale	29.18	4,497	131,222	114,051	Jan 11 04:07 PM
Adsett Roger	Chief Operating Officer	Jan 09 '24	Sale	29.25	3,837	112,232	157,346	Jan 11 04:06 PM
Adsett Roger	Chief Operating Officer	Jan 10 '24	Sale	28.90	3,536	102,190	153,810	Jan 11 04:06 PM
Lewis William	Chair and CEO	Jan 08 '24	Option Exercise	20.49	45,120	924,509	398,489	Jan 10 04:15 PM
Lewis William	Chair and CEO	Jan 08 '24	Sale	29.45	45,120	1,328,973	373,538	Jan 10 04:15 PM
Lewis William	Chair and CEO	Jan 09 '24	Sale	28.72	9,887	283,955	363,651	Jan 10 04:15 PM
Wise John Drayton	Chief Commercial Officer	Jan 03 '24	Option Exercise	19.11	20,071	383,557	124,055	Jan 05 05:33 PM
Wise John Drayton	Chief Commercial Officer	Jan 03 '24	Sale	29.19	20,071	585,872	103,984	Jan 05 05:33 PM
Wise John Drayton	Chief Commercial Officer	Jan 05 '24	Sale	29.32	1,167	34,216	115,690	Jan 05 05:33 PM
Smith Michael Alexander	General Counsel, Senior VP	Jan 05 '24	Sale	29.30	627	18,374	88,737	Jan 05 05:32 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Jan 05 '24	Sale	29.28	1,457	42,661	105,149	Jan 05 05:32 PM
Lewis William	Chair and CEO	Jan 05 '24	Sale	29.26	6,979	204,195	373,538	Jan 05 05:29 PM
Flammer Martina M.D.	Chief Medical Officer	Jan 05 '24	Sale	29.20	1,386	40,478	117,525	Jan 05 05:29 PM
Adsett Roger	Chief Operating Officer	Jan 05 '24	Sale	29.21	3,042	88,864	161,183	Jan 05 05:26 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Dec 28 '23	Option Exercise	20.49	22,288	456,681	116,837	Jan 02 04:04 PM
Schaeffer Orlov S Nicole	Chief People Strategy Officer	Dec 28 '23	Sale	32.00	22,288	713,216	94,549	Jan 02 04:04 PM
Flammer Martina M.D.	Chief Medical Officer	Dec 22 '23	Option Exercise	23.66	28,310	669,815	134,348	Dec 22 04:04 PM
Flammer Martina M.D.	Chief Medical Officer	Dec 22 '23	Sale	30.00	28,310	849,300	106,038	Dec 22 04:04 PM
Bonstein Sara	Chief Financial Officer	Dec 22 '23	Sale	30.00	13,199	395,970	105,241	Dec 22 04:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INSM

Insmed Inc

Upgrade your FINVIZ experience